CVS Health (CVS)
(Delayed Data from NYSE)
$57.57 USD
+0.06 (0.10%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $57.57 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
A Value D Growth D Momentum C VGM
Price, Consensus and EPS Surprise
CVS 57.57 +0.06(0.10%)
Will CVS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CVS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CVS
CVS Health (CVS) Stock Sinks As Market Gains: What You Should Know
Is CVS Health (CVS) a Buy as Wall Street Analysts Look Optimistic?
CVS: What are Zacks experts saying now?
Zacks Private Portfolio Services
CVS Health (CVS) Rises Higher Than Market: Key Facts
CVS Stock Gains From Its Birth Control Prescribing Service Launch
CVS Health Corporation (CVS) Is a Trending Stock: Facts to Know Before Betting on It
Other News for CVS
Noteworthy Monday Option Activity: CVS, BMEA, BWXT
FTC sues prescription drug middlemen, alleging they conspired over high insulin costs
UnitedHealth, Cigna, CVS PBMs targeted by FTC over inflated insulin prices
Dividend Roundup: Microsoft, JPMorgan, CVS Health, Nucor, and more.
American Century Value Fund Q2 2024 Commentary